HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar reiterates a Buy rating on NextCure (NASDAQ:NXTC) and maintains an $8 price target.

May 03, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NextCure's stock rating was reiterated as Buy by HC Wainwright & Co. with a maintained price target of $8.
The reiteration of a Buy rating and maintenance of an $8 price target by a reputable analyst firm like HC Wainwright & Co. can instill confidence in investors and potentially lead to a positive short-term impact on NextCure's stock price. Analyst ratings, especially from well-regarded firms, often influence investor perception and can lead to stock price movements.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100